Transgene Biotek Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2026 inter alia to consider and approve 1) To consider and approve the Un-Audited Financial Results (Standalone & Consolidated) of the Company for the quarter ended 31st December 2025.2) To consider and approve the Limited Review Report (Standalone & Consolidated) for the quarter ended 31st December 2025.3) To transact such other business as may be required.
Disclaimer: This content is for information only and should not be considered investment advice or a recommendation.
For grievances: [email protected]